Pneumocystis Infection in Two Patients Treated with Both Immune Checkpoint Inhibitor and Corticoids

The introduction of immune checkpoint inhibitor (ICI) targeting cytotoxic T-lymphocyte-associated antigen-4 and programmed cell death receptor 1 has dramatically improved clinical outcome for cancer patients. Nevertheless, this treatment can be associated with immune-related adverse events (irAEs) w...

Descripción completa

Detalles Bibliográficos
Autores principales: Sadek, Maroun, Loizidou, Angela, Drowart, Annie, Van den Wijngaert, Sigi, Gomez-Galdon, Maria, Aspeslagh, Sandrine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wolters Kluwer - Medknow 2020
Materias:
Case Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208388/
https://www.ncbi.nlm.nih.gov/pubmed/35756180
http://dx.doi.org/10.4103/JIPO.JIPO_23_19

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9208388/
https://www.ncbi.nlm.nih.gov/pubmed/35756180
http://dx.doi.org/10.4103/JIPO.JIPO_23_19

Ejemplares similares